Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Authors: Borate U; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Tognon CE; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Madanat YF; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX., Misra S; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kaempf A; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Patel PA; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX., Davis KL; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA., Sun J; Department of Statistics, Stanford University, Stanford, CA., Stuani L; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA., Eisenmann ED; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH., Eide CA; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kurtz SE; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Watanabe-Smith K; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Johnson K; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Jager A; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA., Gullaksen SE; Department of Biomedical Data Sciences, Stanford University, Stanford, CA.; Hematology Section, Department of Medicine, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.; Centre of Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Robinson B; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR., Vu T; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR., Plevritis SK; Centre of Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Baker SD; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH., Minnier J; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Clement P; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Avaylon S; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Hayes M; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Newell LF; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gandhi AP; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Leonard J; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Hayes-Lattin B; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Vasu S; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Cook RJ; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Meyers G; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Maziarz RT; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Traer E; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Swords R; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Tyner JW; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Druker BJ; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Saultz JN; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Source: Blood neoplasia [Blood Neoplasia] 2026 Feb 05; Vol. 3 (2), pp. 100205. Date of Electronic Publication: 2026 Feb 05 (Print Publication: 2026).
Publication Type: Clinical Trial; Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42007254
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Borate+U%22">Borate U</searchLink>; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Tognon+CE%22">Tognon CE</searchLink>; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Madanat+YF%22">Madanat YF</searchLink>; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Misra+S%22">Misra S</searchLink>; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Kaempf+A%22">Kaempf A</searchLink>; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Patel+PA%22">Patel PA</searchLink>; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Davis+KL%22">Davis KL</searchLink>; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Sun+J%22">Sun J</searchLink>; Department of Statistics, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Stuani+L%22">Stuani L</searchLink>; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Eisenmann+ED%22">Eisenmann ED</searchLink>; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Eide+CA%22">Eide CA</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Kurtz+SE%22">Kurtz SE</searchLink>; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Watanabe-Smith+K%22">Watanabe-Smith K</searchLink>; Division of Oncological Sciences, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Johnson+K%22">Johnson K</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Jager+A%22">Jager A</searchLink>; Division of Hematology, Oncology and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Gullaksen+SE%22">Gullaksen SE</searchLink>; Department of Biomedical Data Sciences, Stanford University, Stanford, CA.; Hematology Section, Department of Medicine, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.; Centre of Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Robinson+B%22">Robinson B</searchLink>; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Vu+T%22">Vu T</searchLink>; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Plevritis+SK%22">Plevritis SK</searchLink>; Centre of Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Baker+SD%22">Baker SD</searchLink>; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Minnier+J%22">Minnier J</searchLink>; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Clement+P%22">Clement P</searchLink>; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Avaylon+S%22">Avaylon S</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Hayes+M%22">Hayes M</searchLink>; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Newell+LF%22">Newell LF</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Gandhi+AP%22">Gandhi AP</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Leonard+J%22">Leonard J</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Hayes-Lattin+B%22">Hayes-Lattin B</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Vasu+S%22">Vasu S</searchLink>; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Cook+RJ%22">Cook RJ</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Meyers+G%22">Meyers G</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Maziarz+RT%22">Maziarz RT</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Traer+E%22">Traer E</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Swords+R%22">Swords R</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Tyner+JW%22">Tyner JW</searchLink>; Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Druker+BJ%22">Druker BJ</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Saultz+JN%22">Saultz JN</searchLink>; Division of Hematology and Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918841988906676%22">Blood neoplasia</searchLink> [Blood Neoplasia] 2026 Feb 05; Vol. 3 (2), pp. 100205. <i>Date of Electronic Publication: </i>2026 Feb 05 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%2C+Inc%22">Elsevier, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918841988906676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2950-3280 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229503280%22">29503280 </searchLink><i>NLM ISO Abbreviation: </i>Blood Neoplasia <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42007254
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bneo.2026.100205
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100205
    Titles:
      – TitleFull: Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Borate U
      – PersonEntity:
          Name:
            NameFull: Tognon CE
      – PersonEntity:
          Name:
            NameFull: Madanat YF
      – PersonEntity:
          Name:
            NameFull: Misra S
      – PersonEntity:
          Name:
            NameFull: Kaempf A
      – PersonEntity:
          Name:
            NameFull: Patel PA
      – PersonEntity:
          Name:
            NameFull: Davis KL
      – PersonEntity:
          Name:
            NameFull: Sun J
      – PersonEntity:
          Name:
            NameFull: Stuani L
      – PersonEntity:
          Name:
            NameFull: Eisenmann ED
      – PersonEntity:
          Name:
            NameFull: Eide CA
      – PersonEntity:
          Name:
            NameFull: Kurtz SE
      – PersonEntity:
          Name:
            NameFull: Watanabe-Smith K
      – PersonEntity:
          Name:
            NameFull: Johnson K
      – PersonEntity:
          Name:
            NameFull: Jager A
      – PersonEntity:
          Name:
            NameFull: Gullaksen SE
      – PersonEntity:
          Name:
            NameFull: Robinson B
      – PersonEntity:
          Name:
            NameFull: Vu T
      – PersonEntity:
          Name:
            NameFull: Plevritis SK
      – PersonEntity:
          Name:
            NameFull: Baker SD
      – PersonEntity:
          Name:
            NameFull: Minnier J
      – PersonEntity:
          Name:
            NameFull: Clement P
      – PersonEntity:
          Name:
            NameFull: Avaylon S
      – PersonEntity:
          Name:
            NameFull: Hayes M
      – PersonEntity:
          Name:
            NameFull: Newell LF
      – PersonEntity:
          Name:
            NameFull: Gandhi AP
      – PersonEntity:
          Name:
            NameFull: Leonard J
      – PersonEntity:
          Name:
            NameFull: Hayes-Lattin B
      – PersonEntity:
          Name:
            NameFull: Vasu S
      – PersonEntity:
          Name:
            NameFull: Cook RJ
      – PersonEntity:
          Name:
            NameFull: Meyers G
      – PersonEntity:
          Name:
            NameFull: Maziarz RT
      – PersonEntity:
          Name:
            NameFull: Traer E
      – PersonEntity:
          Name:
            NameFull: Swords R
      – PersonEntity:
          Name:
            NameFull: Tyner JW
      – PersonEntity:
          Name:
            NameFull: Druker BJ
      – PersonEntity:
          Name:
            NameFull: Saultz JN
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 02
              Text: 2026 Feb 05
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2950-3280
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Blood neoplasia
              Type: main
ResultId 1